Is Major Pathologic Response the Best Surrogate End Point for Neoadjuvant Trials?

G Gavitt A. Woodard (Gavitt A. Woodard, MD, Division of Thoracic Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT; and Brendon M. Stiles, MD, Division of Thoracic Surgery, Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY) B Brendon M. Stiles (Gavitt A. Woodard, MD, Division of Thoracic Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT; and Brendon M. Stiles, MD, Division of Thoracic Surgery, Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY)

Article Details

Volume / Issue Vol. 44, Issue 5
Published February 10, 2026
Pages 425-426
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (2)

G

Gavitt A. Woodard

Gavitt A. Woodard, MD, Division of Thoracic Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT; and Brendon M. Stiles, MD, Division of Thoracic Surgery, Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY

B

Brendon M. Stiles

Gavitt A. Woodard, MD, Division of Thoracic Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT; and Brendon M. Stiles, MD, Division of Thoracic Surgery, Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY